Validation of novel parallel hematopoietic cell sorter

Information

  • Research Project
  • 6645855
  • ApplicationId
    6645855
  • Core Project Number
    R43HL073553
  • Full Project Number
    1R43HL073553-01
  • Serial Number
    73553
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2003 - 22 years ago
  • Project End Date
    6/30/2005 - 20 years ago
  • Program Officer Name
    MITCHELL, PHYLLIS
  • Budget Start Date
    7/1/2003 - 22 years ago
  • Budget End Date
    6/30/2005 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/19/2003 - 22 years ago

Validation of novel parallel hematopoietic cell sorter

DESCRIPTION (provided by applicant): Hematopoietic cell transplantation is a component of standard therapy for many malignant hematological diseases and is actively being investigated for use in treating non-hematological malignancies and autoimmune diseases, preventing the rejection of solid organ transplants and delivering gene therapy and immune therapy. The use of highly purified hematopoietic stem cells, the only cells responsible for hematopoietic reconstitution, greatly reduces the risks associated with transplantation by eliminating cancer cells and T-cells without increasing the time to engraftment relative to unpurified populations. We propose to build and biologically evaluate a prototype of a novel hematopoietic stem cell sorter that will be immediately applicable to current HCT therapy and will expand the potential use of this treatment to other diseases. The modular cell sorting device is the product of collaboration between two companies, each with unique expertise. It incorporates recent advances in technology that have already been proven in other fields and can achieve sorting speeds of up to 50-100 times that of current fluorescence activated cell sorters. In addition, this device has a self-contained, disposable chip architecture that is substantially less expensive, safer (vis a vis contamination) and more efficient that current technology.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CELLERANT THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    123959400
  • Organization City
    SAN CARLOS
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    940704111
  • Organization District
    UNITED STATES